Pathos AI, a Chicago, IL-based clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, raised $62M in Series C funding.
The round was led by New Enterprise Associates (NEA) with participation from Revolution Growth, Lightbank and Builders VC.
The company intends to use the fund to expand its team of scientists and engineers, accelerate the development of its AI-powered drug development platform, and advance its clinical-stage pipeline of precision oncology therapeutics.
Led by CEO Ryan Fukushima, Pathos is applying its AI platform to acquire additional clinical stage opportunities with phase I results, demonstrating a safe and tolerable profile. It does this using a causal AI framework analyzing changes in expression levels across all genes which are both associated with overall survival and known to be regulated by the mechanism of a given drug. Its AI models are fueled by one of the largest multimodal real-world datasets with patient outcomes, DNA sequencing and RNA sequencing data.
This latest round was completed at a $600M post money valuation, bringing the three-year-old company’s total funding to $102M.
